The RecordAF Study: Design, Baseline Data, and Profile of Patients According to Chosen Treatment Strategy for Atrial Fibrillation

American Journal of Cardiology

Volumn 105, Issue 5, 2010, Pages 687-693

  Heuzey, Jean Yves Le ^a   Breithardt, Günter ^b   Camm, John ^c   Crijns, Harry ^d   Dorian, Paul ^e   Kowey, Peter R ^f   Merioua, Ihsen ^g   Prystowsky, Eric N ^h   Schwartz, Peter J ⁱ   Torp Pedersen, Christian ^j   Weintraub, William ^k  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f LANKENAU HOSPITAL   (United States)

^g SANOFI   (France)

^h ST VINCENT HOSPITAL   (United States)

ⁱ UNIVERSITY OF PAVIA   (Italy)

^j UNIVERSITY OF COPENHAGEN   (Denmark)

^k Christiana Center for Outcomes Research   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; COMORBIDITY; CONTROLLED STUDY; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINUS RHYTHM; VALVULAR HEART DISEASE;

ADRENERGIC BETA-ANTAGONISTS; AGE FACTORS; AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CALCIUM CHANNEL BLOCKERS; CARDIAC GLYCOSIDES; CLINICAL PROTOCOLS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; REGISTRIES; RESEARCH DESIGN;

EID: 76849110820     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.10.012     Document Type: Article

References (21)

1. Go A.S., Hylek E.M., Phillips K.A., Chang Y., Henault L.E., Selby J.V., and Singer D.E. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA 285 (2001) 2370-2375
2. Fuster V., Ryden L.E., Cannom D.S., Crijns H.J., Curtis A.B., Ellenbogen K.A., Halperin J.L., Le Heuzey J.Y., Kay G.N., Lowe J.E., Olsson S.B., Prystowsky E.N., Tamargo J.L., and Wann S. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J 2006 27 (2006) 1979-2030
3. Lafuente-Lafuente C., Mouly S., Longas-Tejero M.A., Mahe I., and Bergmann J.F. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med 166 (2006) 719-728
4. Carlsson J., Miketic S., Windeler J., Cuneo A., Haun S., Micus S., Walter S., and Tebbe U. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol 41 (2003) 1690-1696
5. Van Gelder I.C., Hagens V.E., Bosker H.A., Kingma J.H., Kamp O., Kingma T., Said S.A., Darmanata J.I., Timmermans A.J., Tijssen J.G., and Crijns H.J. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 347 (2002) 1834-1840
6. Wyse D.G., Waldo A.L., DiMarco J.P., Domanski M.J., Rosenberg Y., Schron E.B., Kellen J.C., Greene H.L., Mickel M.C., Dalquist J.E., and Corley S.D. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347 (2002) 1825-1833
7. Le Heuzey J.Y., Paziaud O., Piot O., Said M.A., Copie X., Lavergne T., and Guize L. Cost of care distribution in atrial fibrillation patients: the COCAF study. Am Heart J 147 (2004) 121-126
8. Nieuwlaat R., Capucci A., Camm A.J., Olsson S.B., Andresen D., Davies D.W., Cobbe S., Breithardt G., Le Heuzey J.Y., Prins M.H., Levy S., and Crijns H.J. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 26 (2005) 2422-2434
9. McCabe J.M., Johnson C.J., and Marcus G.M. Internal medicine physicians' perceptions regarding rate versus rhythm control for atrial fibrillation. Am J Cardiol 103 (2009) 535-539
10. World Medical Association General Assembly. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Int Bioethique 15 (2004) 124-129
11. International Epidemiological Association (IEA). Good Epidemiological Practice (GEP)-IEA Guidelines for proper conduct of epidemiological research. http://www.ieaweb.org Accessed 5 November 2009
12. Kirchhof P., Auricchio A., Bax J., Crijns H., Camm J., Diener H.C., Goette A., Hindricks G., Hohnloser S., Kappenberger L., Kuck K.H., Lip G.Y., Olsson B., Meinertz T., Priori S., Ravens U., Steinbeck G., Svernhage E., Tijssen J., Vincent A., and Breithardt G. Outcome parameters for trials in atrial fibrillation: executive summary. Eur Heart J 28 (2007) 2803-2817
13. The EuroQol Group. EQ-5D: A standardised instrument for use as a measure of health outcome. www.euroqol.org/ Accessed 5 November 2009
14. Dorian P., Paquette M., Newman D., Green M., Connolly S.J., Talajic M., and Roy D. Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation. Am Heart J 143 (2002) 984-990
15. Go A.S., Hylek E.M., Phillips K.A., Chang Y., Henault L.E., Selby J.V., and Singer D.E. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA (2001) 2370-2375
16. Miyasaka Y., Barnes M.E., Gersh B.J., Cha S.S., Bailey K.R., Abhayaratna W.P., Seward J.B., and Tsang T.S. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 114 (2006) 119-125
17. Lévy S., Maarek M., Coumel P., Guize L., Lekieffre J., Medvedowsky J.L., Sebaoun A., and College of French Cardiologists. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. Circulation 99 (1999) 3028-3035
18. Meiltz A., Zimmermann M., Urban P., and Bloch A. Atrial fibrillation management by practice cardiologists: a prospective survey on the adherence to guidelines in the real world. Europace 10 (2008) 674-680
19. Nabauer M., Gerth A., Limbourg T., Schneider S., Oeff M., Kirchhof P., Goette A., Lewalter T., Ravens U., Meinertz T., Breithardt G., and Steinbeck G. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace 11 (2009) 423-434
20. Kerr C., Boone J., Connolly S., Greene M., Klein G., Sheldon R., and Talajic M. Follow-up of atrial fibrillation: the initial experience of the Canadian Registry of Atrial Fibrillation. Eur Heart J 17 Suppl C (1996) 48-51
21. Hohnloser S.H., Kuck K.H., and Lilienthal J. Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 356 (2000) 1789-1794